(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2022 (17.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/053990 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
A61K 31/454 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2021/058229

(22) International Filing Date:
10 September 2021 (10.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/078,211	14 September 2020 (14.09.2020)	US
63/106,302	27 October 2020 (27.10.2020)	US
63/185,357	06 May 2021 (06.05.2021)	US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **BARDY BOUXIN, Nathalie Annie**; c/o Pfizer International Operations, 23-25 avenue du Docteur Lannelongue, 75014 Paris (FR). **BARRY, Eloisa Virginia**; 1451 Washington Street, Canton, Massachusetts 02021 (US). **BLAKE-HASKINS, John Andrew**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **CHAN, Geoffrey Wing-Lynn**; 506 Alexander Avenue, #25, Cape May Point, New Jersey 08212 (US). **CHOU, Jeffrey**; 34018 Stetson Way, Fremont, California 94555 (US). **ELMELIEGY, Mohamed A**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **KRUPKA, Heike Iris**; 2737 Christopher Court, Hayward, California 94541 (US). **LIAO, Kai Hsin**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **VANDENDRIES, Erik Rene**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **VIQUEIRA, Andrea**; c/o Pfizer, S.L., Avenida de Europa 20-B, Parque Empresarial "La Moraleja", 28108 Alcobendas Madrid (ES). **WISSEL, Paul Stephen**; c/o Pfizer Inc., 500 Arcola Road, Collegeville, Pennsylvania 19426 (US). **YVER, Anne**; c/o Pfizer International Operations, 23-25 avenue du Docteur Lannelongue, 75014 Paris (FR).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2022/053990 A1

(54) Title: METHODS, THERAPIES AND USES FOR TREATING CANCER

(57) Abstract: The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.